Although the other five genes RPL32, TMEM59L, LOC642929, LHX2, and TLCD3B have not been identified in clinical studies indicating their effect on cancers, they may be considered candidate oncogenes because of their high ranking in our constructed gene network modules. This evidence concerns the gene RPL32 and cancer.